It has also been seen that in prostate cancer cells (DU-145), MSA acts by upregulation of CDK inhibitors (CDKIs) including p16/INK4a, p21/CIP1 and p27/KIP1. The gene discussed is CDKN2A; the disease is prostate carcinoma.